In CDK4/6i–treated luminal breast cancers that have entered senescence, newly activated enhancers are heavily enriched for AP-1 transcription factor binding (especially c-Jun, JunB, and Fra-2; ref. 30). This evidence concerns the gene FOSL2 and breast cancer.